CD86 and lung carcinoma: As shown in Fig 1A, DC-based HHP lung cancer vaccine [HHP+poly(I:C)] displays significantly higher expression of CD80, CD83, HLA-DR and CD86 than control immature DC [iDC], DC pulsed with HHP-killed cells alone [HHP] or DC stimulated only with poly(I:C) [poly(I:C)].